Rocket Pharmaceuticals Reaches FDA Alignment in Danon Heart Disease Treatment Trial
By Ben Glickman
Rocket Pharmaceuticals said it had reached alignment with the Food and Drug Administration on its Phase 2 trial of its treatment for Danon disease.
The Cranbury, N.J.-based pharmaceutical company said its study would evaluate the use of RP-A501 to treat 12 patients with Danon disease, a fatal cardiomyopathy with no cure. The Phase 2 trial will be an open-label study with a biomarker-based co-primary endpoint assessed after 12 months, the company said.
The trial will support accelerated approval of Rocket's treatment by the FDA.
The company said it expected to file its Clinical Trial Application/Investigational Medicinal Product Dossier for RP-A501, which will allow for studies to take place in the European Union in the third quarter.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
September 12, 2023 16:40 ET (20:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing